Fidelity Investments
SYRE icon

Fidelity Investments’s Spyre Therapeutics SYRE Stock Holding History

Fidelity Investments’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16B Buy
13,026,187
+1,245,163
+11% +$90.9M 0.05% 285
2026
Q1 		$594M Buy
11,781,024
+142,205
+1% +$5.36M 0.03% 452
2025
Q4 		$381M Buy
11,638,819
+2,578,675
+28% +$67.4M 0.02% 610
2025
Q3 		$152M Buy
9,060,144
+7,110
+0.1% +$116K 0.01% 977
2025
Q2 		$136M Buy
9,053,034
+14,481
+0.2% +$214K 0.01% 981
2025
Q1 		$146M Buy
9,038,553
+237,287
+3% +$4.94M 0.01% 933
2024
Q4 		$205M Buy
8,801,266
+1,177,385
+15% +$34.5M 0.01% 816
2024
Q3 		$224M Buy
7,623,881
+115,898
+2% +$3.23M 0.01% 792
2024
Q2 		$177M Buy
7,507,983
+924,228
+14% +$31.2M 0.01% 829
2024
Q1 		$247M Buy
6,583,755
+2,797,878
+74% +$81.1M 0.02% 716
2023
Q4 		$79.7M Buy
+3,785,877
New +$52.2M 0.01% 1098
2022
Q3 		– Sell
-60
Closed -$1K – 5381
2022
Q2 		$1K Buy
60
+55
+1,100% +$1.93K ﹤0.01% 4801
2022
Q1 		$0 Buy
+5
New +$420 ﹤0.01% 5464

Other funds holding SYRE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments's SYRE Position: Q2 2026 in Review

Fidelity Investments increased its Spyre Therapeutics (SYRE) stake by 11% in Q2 2026, buying an estimated $90.9M and bringing the position to 13,026,187 shares worth $1.16B. The position accounts for 0.05% of the portfolio, ranked #285.

Fidelity Investments first reported a position in SYRE in Q1 2022 and has held it in 13 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Fidelity Investments held 13,026,187 shares of Spyre Therapeutics worth $1.16B as of Q2 2026.
  • Fidelity Investments bought 1,245,163 Spyre Therapeutics shares in Q2 2026, an estimated $90.9M.
  • Spyre Therapeutics made up 0.05% of Fidelity Investments's portfolio in Q2 2026, its #285 holding.
  • Fidelity Investments first reported a position in Spyre Therapeutics in Q1 2022 and has held it in 13 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.